• Sign in
  • 1744009905_435.svg 1744009905_642.svg

  • Latest news
  • Top headlines
  • Most read
  • Columnists
O'zbekcha
Ўзбекча
Русский
  • O'zb
  • Ўзб
  • Рус
  • Eng
  • O'zb
  • Ўзб
  • Рус
  • Eng
  • Latest news
  • Top headlines
  • Most read
  • Columnists
    • USD12705.79
    • RUB159.2
    • EUR14704.41
    • Google play
    • App Store
    • Telegram
    • Daryo
      • About Daryo
      • Editorial office
      • Contact us
      • Terms of use
      • Privacy policy
      • News archive
    • Advertisement
    • Social networks
      • Instagram | Main
      • Instagram | Lifestyle
      • Instagram | Sport
      • Facebook | Main
      • OK | Main
      • YouTube | Daryo
      • YouTube | Daryo in Russian
      • YouTube | Daryo Global
    Telegram Youtube Facebook Instagram Twitter vkontakte
    Daryo logo white
    • Uzbekistan
      • Others
      • Navoi
      • Tashkent region
      • Syrdarya
      • Jizzakh
      • Kashkadarya
      • Surkhandarya
      • Khorezm
      • Bukhara
      • Samarkand
      • Namangan
      • Fergana
      • Andijan
      • Karakalpakstan
      • Tashkent City
      • DaryoKindness
      • Weather
    • Central Asia
      • Uzbekistan
      • Afghanistan
      • Kyrgyzstan
      • Kazakhstan
      • Turkmenistan
      • Tajikistan
    • World
    • Money
      • Business
      • Economics
      • Finance
      • Crypto
    • Culture
      • Movies
      • Books
      • Music
      • Celebrities
    • Lifestyle
      • Women only
        • Children
        • Beauty
        • Carrier
        • Advises
        • Fashion
        • Recipes
      • Technology
        • Architecture
        • Gadjets
        • Science
        • Space
        • Media
      • Auto
      • Entertainment
      • Travel
      • Health
      • Education
        • Entrant
        • Learn english
    • Sport
      • Football
      • UFC
      • Boxing
    infinix
    Daryo.uz - Login
    Daryo.uz Daryo.uz
    Daryo.uz - Login
    World

    Alzheimer's breakthrough: approved drugs slow disease progression

    Alzheimer's breakthrough: approved drugs slow disease progression

    The recent full approval of the Alzheimer's drug Leqembi and the potential upcoming approval of Eli Lilly's donanemab mark a significant milestone in the treatment of the disease. These medications have been proven to slow the progression of memory loss and the loss of daily functioning associated with Alzheimer's, as CNN reported on July 17.

    Photo: Dr. Seth Gale points out evidence of Alzheimer?s disease on PET scans at the Center for Alzheimer Research and Treatment (CART) at Brigham And Women?s Hospital in Boston, Massachusetts, U.S., 2023
    Source: Reuters

    The Phase 3 clinical trial results presented at the Alzheimer's Association International Conference showcased the effectiveness of donanemab in delaying the disease's progression. Lilly has completed its submission to the US Food and Drug Administration for donanemab and anticipates regulatory action by the end of the year.

    In the laboratory of University College London, trials are led by Dr. Catherine Mummery, a doctor of medical sciences. 

    "In fact, we are planning to start a trial called 'Primary Prevention in People with Genetic Alzheimer's Disease.' They know that they have the mutation, but it will take about 25 years before the first symptoms manifest. Our goal is to determine whether offering them anti-amyloid therapy can prevent the development of the disease. We plan to begin in the next few months, and I think it is truly interesting," says Mummery.

    While the drugs represent the first breakthrough in slowing Alzheimer's progression, experts have raised questions about the extent of their benefits. In a series of editorials in the Journal of the American Medical Association, researchers questioned the degree of clinical benefit observed in the trials.

    Both Leqembi and donanemab work by targeting and clearing the amyloid protein, a hallmark of Alzheimer's, in the brain. The trial results showed that patients taking these medications experienced a 35% slower disease progression compared to those on a placebo, as measured by the integrated Alzheimer's Disease Rating Scale (iADRS). However, experts have highlighted the comparatively modest clinical effect and the need for more impactful and safer treatments.

    The trial also indicated that the benefit was more prominent in patients with low to medium levels of another Alzheimer's-associated protein called tau. Patients in the low/medium tau category experienced a 35% slowing of disease progression on the iADRS scale, equating to a 4.4-month decline delay over the 18-month trial period.

    The safety profile of these drugs is a concern, with adverse events such as brain swelling or bleeds observed in some patients. The drugs are administered through intravenous infusion, and infusion reactions can also occur. Additionally, the medications are costly, with Leqembi priced at $26,500 per year.

    Experts emphasise the need for longer-term study to assess the drugs' benefits over extended periods. They also stress the importance of addressing issues related to cost, administration complexity, and safety.

    Despite these considerations, the approval of these medications provides hope for patients and their families, who previously faced a lack of effective treatment options. The drugs offer the potential to alter the trajectory of the disease and improve outcomes for individuals with Alzheimer's. 

    18.07.2023, 11:40   Comments (0)   595
    Facebook Twitter LinkedIn Telegram Email

    Comments (0)

    Sign in
    Leave A Reply Cancel

    On this topic

    Russian President Putin vows Response to Crimea bridge attack, calls it "terrorist act"

    18.07.2023, 11:38

    UN pact facilitating Russian grain and fertilizer exports terminated as Russia withdraws from Black Sea Initiative, says Secretary-General Guterres

    18.07.2023, 11:09

    Unknown virus spreads rapidly across Egypt

    18.07.2023, 09:40

    Taiwan detects record number of Chinese naval ships on its territory

    18.07.2023, 03:50

    Israel recognizes territorial sovereignty of Morocco over Western Sahara

    18.07.2023, 03:41

    Erdogan embarks on three-day tour of Arab Gulf states to boost economic ties

    18.07.2023, 03:12
    ×Lightbox Image

    Daryo.uz | Solution to your problems


    Beepul 's rising popularity: 3.5x user growth, transaction up 2.3x in 2024


    Don't want to waste time standing in lines? Pay your utility bills through the Ipoteka Retail mobile app?


    Beeline Uzbekistan started 2025 with a significant network modernization


    More than 500,000 new users: residents of Uzbekistan choose the Hambi superapp

     

    Recommended

    "Visa simplification with Uzbekistan could be on the table," EU Ambassador Klaar points out

    11 June, 12:12

    “Uzbekistan is undergoing large-scale reforms and transformation,” says EU business leader at TIIF

    11 June, 08:34

    Central Bank warns half of monthly income goes to loans as debt burden rises in Uzbekistan

    3 June, 12:34

    Uzbekistan’s foreign trade turnover reaches $24.6bn in 4M25, up 16.3% y/y

    22 May, 11:29
     
     
     

    Latest news

    Volkswagen, Uzavtosanoat partner to launch full-scale car production in Uzbekistan by late 2025

    Uzbekistan | 13 June, 15:24

    Tashkent International Investment Forum 2025 secures $30.5bn in deals, nearly tripling 2023 figures

    Uzbekistan | 13 June, 14:01

    Rosatom to build two large and small nuclear reactors in Uzbekistan

    Uzbekistan | 13 June, 11:31

    Uzbek Embassy in Israel urges citizens to take shelter as tensions escalate amid Israeli strikes on Iran

    Uzbekistan | 13 June, 10:12

    TIIF 2025 wraps up with over 20 promising deals across sectors

    Uzbekistan | 13 June, 09:00

    EBRD commits $250mn to modernize Uzbekistan’s irrigation system and boost energy efficiency

    Uzbekistan | 12 June, 17:15

    Uzbekistan signs investment agreements with Afghanistan, Japan, and global partners at TIIF 2025

    Uzbekistan | 12 June, 14:32

    Uzbekistan holds policy rate at 14% to curb inflation

    Uzbekistan | 12 June, 13:07
    Daryo About Us

    Full reproduction or partial quoting of material, as well as the use of photographic, graphic, audio and/or video materials of Daryo (the Uzbek Press and Information Agency (UzAPI, now the Agency for Information and Mass Communications under the Presidential Administration of the Republic of Uzbekistan) is registered on 13.03.2015 with certificate number No. 0944 as a mass media) is allowed if there is a hyperlink to the website daryo.uz and/or are accompanied by a note indicating the authorship of the online publication Daryo. Individual publications may contain information that is not intended for users under the age of 18. Info@daryo.uz

    Telegram Youtube Facebook Instagram Twitter vkontakte

    © Simple Networking Solutions, 2013–2025

    Age restriction

    Did you find a bug? Press Ctrl + Enter

    • Terms of use
    • Privacy policy
    • Advertisement
    What are we going to search for?

    Sign In or Register

    Welcome Back!

    Login below or Register Now.

    Google

    or with email

    Leaving a comment, Пользовательского соглашения and Политики конфиденциальности

    Register Now

    Already registered? Login.

    Google

    or with email

    A password will be e-mailed to you.

    Leaving a comment, Пользовательского соглашения and Политики конфиденциальности

    Found an error in the text?

    ×

    Thank you. We have received your message and will fix the error as soon as possible.